What are the benefits and risks of transcranial magnetic stimulation (TMS) for adults with treatment‑resistant major depressive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Benefits and Risks of TMS for Treatment-Resistant Major Depressive Disorder

TMS should be used in adults with major depressive disorder who have failed to respond to at least 2 adequate pharmacologic trials, as it provides meaningful symptom reduction and remission with minimal adverse effects. 1

Clinical Benefits

Efficacy in Treatment-Resistant Depression

The aggregate evidence demonstrates that rTMS significantly improves depressive symptoms and facilitates remission compared to sham treatment, with a number needed to treat of 3.4 to 9 patients for response and 5 to 7 patients for remission 1. Recent meta-analyses confirm response rates of approximately 29% in controlled trials, with remission rates reaching 42% in real-world settings 2, 3, 4.

  • High-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation shows the most robust evidence base 1
  • Theta burst stimulation (TBS) demonstrates comparable efficacy to conventional 10-Hz protocols but in significantly shorter treatment sessions 1
  • Bilateral stimulation protocols show strong efficacy with SUCRA probabilities ranking among the top interventions 5

Important Caveat on Efficacy

One recent veteran-specific RCT found no significant differences between active rTMS and sham treatment in 164 patients with treatment-resistant depression and high rates of comorbid PTSD and substance use disorder 1. This raises the possibility that placebo effects from frequent clinical visits and patient expectancy may contribute substantially to outcomes. However, this single study was not sufficient to overturn the broader evidence base showing benefit 1.

Safety Profile and Adverse Effects

Minimal Serious Risks

TMS carries a low risk profile with no increased dropout rates due to adverse events (3.3% active vs 2.3% sham) or serious adverse events (0.9% active vs 1.5% sham) 6. The safety classification indicates:

  • Low overall risk for standard rTMS protocols 7
  • Medium risk for seizure induction, though this remains rare 7
  • No evidence of tissue damage with proper protocols 7

Common Non-Serious Adverse Effects

The following side effects occur more frequently with active TMS but are typically mild and transient 6:

  • Headaches: 22.6% (active) vs 16.2% (sham) - OR 1.48
  • Pain at stimulation site: 23.8% (active) vs 5.2% (sham) - OR 8.09
  • Discomfort: 10.9% (active) vs 5.0% (sham) - OR 1.98
  • Scalp discomfort and noise during treatment 7
  • Transient tingling, skin itching, or burning sensations 7

These effects resolve quickly after treatment and rarely lead to discontinuation 1, 6.

Treatment Parameters and Practical Considerations

Standard Protocol

  • 20-30 treatment sessions delivered over 4-6 weeks 1
  • Daily weekday sessions requiring frequent onsite visits
  • Left prefrontal DLPFC targeting using standardized or neuronavigation-guided localization 1, 8

Accelerated and Alternative Protocols

  • Theta burst stimulation reduces session time from 37.5 minutes to 3-10 minutes with similar efficacy 1
  • Accelerated protocols (e.g., Stanford Neuromodulation Therapy) show promising preliminary results but require replication 3
  • Insufficient evidence currently exists to recommend for or against intermittent TBS over standard rTMS 1

Critical Access Barrier

The primary challenge for rTMS implementation is access, as treatment requires frequent onsite visits over 4-6 weeks 1. This logistical burden limits real-world applicability despite demonstrated efficacy.

Comparison to Other Treatments

When compared to cognitive behavioral therapy (CBT) and antidepressants as first-line treatments, TMS is reserved for second-step therapy after medication failures 9, 10. However, TMS demonstrates superior tolerability compared to ECT, with fewer cognitive side effects and no requirement for anesthesia 2.

Predictive Factors and Personalization

No reliable method currently exists to predict which patients will respond before treatment begins 3. However, emerging evidence suggests:

  • Patients with greater frontal lobe volume show better response rates 7
  • Structural brain atrophy may interfere with treatment responsiveness 7
  • Resting-state connectivity measures show promise as biomarkers but remain outside routine clinical use 3, 11

When to Use TMS

Initiate TMS after failure of 2 or more adequate antidepressant medication trials 1. Consider earlier in treatment algorithms for patients who:

  • Cannot tolerate medication side effects
  • Prefer non-pharmacologic interventions
  • Have contraindications to antidepressants

Do not delay TMS indefinitely in treatment-resistant cases, as the benefits clearly outweigh the minimal and manageable adverse events 1.

References

Related Questions

What is transcranial magnetic stimulation (TMS) and how is it used to treat treatment‑resistant major depressive disorder?
Can a patient who recently had a large abdominal surgery and has a history of major depressive disorder safely begin transcranial magnetic stimulation (TMS) now?
Can you create a psychoeducational graphic on repetitive transcranial magnetic stimulation (rTMS) for treatment‑resistant depression in adults?
What are the potential adverse effects and administration protocols of Transcranial Magnetic Stimulation (TMS)?
Does the FDA‑cleared NeuroStar protocol for obsessive‑compulsive disorder use a figure‑8 coil instead of an H7 coil, and is the figure‑8 coil sufficiently effective despite its lower penetration depth compared to the H7 coil?
What is the step‑by‑step management of a newly diagnosed diabetic patient with a random blood glucose of 300 mg/dL, no organ damage, and clinically stable?
In a patient with acute pulmonary embolism and active upper gastrointestinal bleeding who cannot receive anticoagulation, what is the role of an inferior vena cava (IVC) filter?
What is the recommended pediatric dosing regimen for initiating lithium therapy, including starting dose and titration guidelines?
What is the appropriate duration of nitrofurantoin (Macrobid) treatment for an acute urinary tract infection in an elderly female?
When is it appropriate to switch lithium from thrice-daily dosing to once-daily dosing, and which formulation should be used?
In a 38-year-old male chronic alcoholic presenting with epigastric discomfort, bloating, and gas, what is the most likely diagnosis and appropriate treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.